Combination therapy improves clinical outcomes in allergic asthma, suggesting potential for enhanced treatment.
Omalizumab, SCIT-HDM, and their combination improved outcomes over 36 months. Combination therapy showed the most consistent benefits, but results should be interpreted cautiously due to the small sample size. Further studies are needed.
No takes yet. Share an insight, caveat, or question.
Bożek et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: